Corvus Pharmaceuticals
CRVS
48 hedge funds and large institutions have $33.8M invested in Corvus Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 13 increasing their positions, 11 reducing their positions, and 7 closing their positions.
18% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 11
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.06% less ownership
Funds ownership: 39.18% → 39.12% (-0.06%)
0% less capital inflows, than outflows
Capital inflows: $853K | Capital outflows: $856K
8% less funds holding
Funds holding: 52 → 48 (-4)
45% less call options, than puts
Call options by funds: $86K | Put options by funds: $157K
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$242K |
| 2 |
TL
TowerView LLC
New York
|
+$138K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$135K |
| 4 |
SC
Samlyn Capital
New York
|
+$132K |
| 5 |
Morgan Stanley
New York
|
+$98.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$289K |
| 2 |
Two Sigma Investments
New York
|
-$135K |
| 3 |
JP Morgan Chase
New York
|
-$101K |
| 4 |
Millennium Management
New York
|
-$98.2K |
| 5 |
Goldman Sachs
New York
|
-$72K |
CRVS Hedge Fund Activity: Q4 2023 in Review
48 of the 6,873 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q4 2023, worth a combined $33.8M — up 21% from $28M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of CRVS and 3 opened new positions — a net loss of 4 holders — while 11 trimmed existing stakes and 13 added.
The largest buyer was Renaissance Technologies, adding an estimated $242K. The largest seller was Marshall Wace, exiting entirely with an estimated $289K sold.
- 48 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q4 2023, down from 52 in Q3 2023.
- Funds reported $33.8M of Corvus Pharmaceuticals stock for Q4 2023, up 21% quarter-over-quarter.
- 3 funds opened new Corvus Pharmaceuticals positions in Q4 2023 and 7 closed out, a net change of -4 holders.
- The largest Corvus Pharmaceuticals buyer in Q4 2023 was Renaissance Technologies, an estimated $242K added.
- The largest Corvus Pharmaceuticals seller in Q4 2023 was Marshall Wace, an estimated $289K sold.
Based on aggregated 13F filings for Q4 2023.